These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30047303)

  • 21. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
    Pathak D; Chadha N; Silakari O
    J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
    Song A; Zhang J; Ge Y; Wang C; Meng Q; Tang Z; Peng J; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 May; 25(10):2724-2729. PubMed ID: 28385595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics and pharmacophore modelling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC.
    Singh PK; Silakari O
    SAR QSAR Environ Res; 2017 Mar; 28(3):221-233. PubMed ID: 28290719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
    Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
    Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
    Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
    Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
    Ai X; Sun Y; Wang H; Lu S
    Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFRT790M.
    Çoban G
    J Biomol Struct Dyn; 2024; 42(2):571-597. PubMed ID: 37029759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
    Agarwal SM; Pal D; Gupta M; Saini R
    Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
    Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
    J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
    Sos ML; Rode HB; Heynck S; Peifer M; Fischer F; Klüter S; Pawar VG; Reuter C; Heuckmann JM; Weiss J; Ruddigkeit L; Rabiller M; Koker M; Simard JR; Getlik M; Yuza Y; Chen TH; Greulich H; Thomas RK; Rauh D
    Cancer Res; 2010 Feb; 70(3):868-74. PubMed ID: 20103621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.
    Park H; Jung HY; Mah S; Hong S
    Angew Chem Int Ed Engl; 2017 Jun; 56(26):7634-7638. PubMed ID: 28493467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
    Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D
    J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico analysis of the effect of mutation on epidermal growth factor receptor in non-small-cell lung carcinoma: from mutational analysis to drug designing.
    Zhao FL; Yang GH; Xiang S; Gao DD; Zeng C
    J Biomol Struct Dyn; 2017 Feb; 35(2):427-434. PubMed ID: 26813338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
    Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
    J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.